Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study
Delveinsight
DECEMBER 3, 2020
A&E’s portfolio covers a complete line of sternum closure devices, comprising of suture, fixation and cable systems, plus a range of disposable products such as pacing wires and punch tools utilized for tissue biopsies. Merck chooses TriNKET cancer immunotherapy program.
52 
Let's personalize your content